Navigation Links
Brian Levy, OD, MSc, Named Chief Operating Officer of Danube Pharmaceuticals

NEW YORK, June 23 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Brian Levy, OD, MSc as its Chief Operating Officer.

"Dr. Levy's depth and breathe of experience in clinical operations, drug and device development and medical affairs make him an excellent addition to Danube's senior management team. I look forward to his working with us in successfully developing our drug candidates and expanding our pipeline," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.

Prior to joining Danube, since 2004, Dr. Levy served as Corporate Vice President and Chief Medical Officer of Bausch & Lomb worldwide. He was responsible for clinical development and research, global product safety and medical affairs. In this role Dr. Levy drove the development and subsequent approval of multiple ophthalmic pharmaceutical products and ophthalmic devices globally, including the only approved intra-ocular sustained release steroid drug delivery system. Dr. Levy joined Bausch & Lomb in 1994 as Director, Medical Clinical Affairs. Prior to joining Bausch & Lomb, from 1989 to 1994, Dr. Levy served as Associate Professor in the Department of Ophthalmology at California Pacific Medical Center in San Francisco. Before that he studied epidemiology and biostatistics in vision research through the National Institutes of Health and then proceeded into private clinical practice for 10 years. During this period Dr. Levy was a clinical investigator for numerous products in development and an advisor and consultant to the ophthalmic industry.

Dr. Levy currently holds an appointment as Clinical Professor in the Department of Ophthalmology at the University of Rochester's School of Medicine. He received a Doctor of Optometry degree from the University of California at Berkeley and did his post-graduate work in comparative anatomy and physiology of the eye at the University of Waterloo in Canada, where he received a Master of Science degree. Dr. Levy has published widely in peer-reviewed journals and has presented nationally and internationally at scientific and educational symposia of Ophthalmology.

About Danube Pharmaceuticals, Inc.

Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statements. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, and product pricing and third party reimbursement. We undertake no obligation to update any forward-looking statement contained in this press release, except as required by law.

SOURCE Danube Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
2. MiMedx Announces Brian J. Splan as President
3. MedImmunes Brian Rosen Honored by Montgomery County Chamber at 49th Annual Awards Dinner
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
6. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
7. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
8. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
9. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
10. Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
(Date:11/30/2015)... 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the ... C.W. Wong to its Board of Directors to replace ... with a wealth of experience as co-founder of Resverlogix, with ... --> --> Dr. Wong remarked, ... of directors. Zenith,s long standing expertise in epigenetics and the ...
(Date:11/30/2015)... -- TapImmune, Inc. (TPIV), a clinical-stage ... and gene-based immunotherapeutics and vaccines for the treatment of ... presenting at the 8 th Annual LD Micro ... PT. Dr. John N. Bonfiglio a TapImmune ... presentation and will join TapImmune management in meeting with ...
(Date:11/30/2015)... 2015  Northwest Biotherapeutics (NASDAQ: NWBO ) ("NW ... therapies for solid tumor cancers, announced today that the ... and the Company welcomes Neil Woodford,s call ... anonymous internet report on NW Bio.  The Company,s Board ... Powers stated, "We agree with Mr. Woodford that, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, ... applied spectroscopy, covers a wide range of applications such as, but not limited ...
Breaking Biology Technology:
(Date:11/4/2015)... York , November 4, 2015 ... a new market report published by Transparency Market Research "Home ... Growth, Trends and Forecast 2015 - 2022", the global home ... US$ 30.3 bn by 2022. The market is estimated ... forecast period from 2015 to 2022. Rising security needs ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... a partnership with 2XU, a global leader in ... a smart hat with advanced bio-sensing technology. The ... athletes to monitor key biometrics to improve overall ... partnership, the two companies will bring together the most ...
Breaking Biology News(10 mins):